Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013.
暂无分享,去创建一个
R. Crystal | S. Harper | L. Zoloth | B. Tannous | Y. Ikeda | T. Weber | H. Federoff | Y. Fong | D. Sterman | A. Asokan | L. Vandenberghe | D. Kohn | M. Sena-Esteves | S. Boye | P. Monahan | W. Goins | W. Wierda | J. Gray | P. Adusumilli | Satiro De Oliveira | Cheryl L. McDonald | J. Adair | M. Abedi | A. Patterson | D. Rosenblum | L. Popplewell | Jacqueline Corrigan‐Curay | Marina O’reilly | R. Jambou | E. Rosenthal | Nabil Ahmed | L. Prograis | R. Gopal‐Srivastava | L. Gargiulo | Maureen Montgomery | Satiro N De Oliveira | R. Gopal‐srivastava
[1] M. Hauser,et al. RNAi-mediated Gene Silencing of Mutant Myotilin Improves Myopathy in LGMD1A Mice , 2014, Molecular therapy. Nucleic acids.
[2] W. Hauswirth,et al. Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A. , 2014, Human gene therapy methods.
[3] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[4] U. Gerdemann,et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[5] R. Samulski,et al. An emerging adeno-associated viral vector pipeline for cardiac gene therapy. , 2013, Human gene therapy.
[6] R. Crystal,et al. Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease. , 2013, Human gene therapy.
[7] D. Elashoff,et al. Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy. , 2013, Human gene therapy.
[8] Y. Kew,et al. Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] A. Thrasher,et al. Gene therapy for PIDs: Progress, pitfalls and prospects , 2013, Gene.
[10] A. Fischer,et al. Gene therapy of primary T cell immunodeficiencies. , 2013, Gene.
[11] Michael L Kaufman,et al. β-globin gene transfer to human bone marrow for sickle cell disease. , 2013, The Journal of clinical investigation.
[12] Matthew L Baker,et al. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy , 2013, Molecular therapy. Nucleic acids.
[13] Michael L Kaufman,et al. Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[14] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[15] W. Hauswirth,et al. AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. , 2013, Human gene therapy.
[16] W. Hauswirth,et al. Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus , 2013, Gene Therapy.
[17] Aaron R Cooper,et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. , 2012, Blood.
[18] K. Purpura,et al. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. , 2012, Human gene therapy methods.
[19] Paul D. Gamlin,et al. The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. , 2012, Human gene therapy.
[20] Lucas V. Greder,et al. Transgene‐Free Disease‐Specific Induced Pluripotent Stem Cells from Patients with Type 1 and Type 2 Diabetes , 2012, Stem cells translational medicine.
[21] Jinjuan Wang,et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. , 2012, Blood.
[22] David V Schaffer,et al. The AAV Vector Toolkit: Poised at the Clinical Crossroads. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] G. Dranoff,et al. Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.
[24] P. Davis. An unparalleled engine for discovery and clinical introduction: the clinical and translational science awards and gene therapy. , 2012, Human gene therapy.
[25] M. Chuah,et al. Clinical progress in gene therapy: sustained partial correction of the bleeding disorder in patients suffering from severe hemophilia B. , 2012, Human gene therapy.
[26] Pratima Chowdary,et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.
[27] A. Thrasher,et al. Gene therapy for primary immunodeficiency , 2011, Current opinion in pediatrics.
[28] Adrian P Gee,et al. Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.
[29] S. Frantz. Engineered T-cell therapy shows efficacy in blood cancer , 2011, Nature Biotechnology.
[30] W. Hauswirth,et al. Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. , 2011, Investigative ophthalmology & visual science.
[31] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[32] Hao Liu,et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.
[33] Frederic D. Bushman,et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. , 2010, The New England journal of medicine.
[34] W. Hauswirth,et al. Functional and Behavioral Restoration of Vision by Gene Therapy in the Guanylate Cyclase-1 (GC1) Knockout Mouse , 2010, PloS one.
[35] Alessandro Aiuti,et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.
[36] I. Kerridge,et al. Accepting risk in clinical research: is the gene therapy field becoming too risk-averse? , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[37] J. Kimmelman. Tomorrow, Interrupted?: Risk, Ethics, and Medical Advance in Gene Transfer. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[38] A. Zwinderman,et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[39] Hao Liu,et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.
[40] W. Hauswirth,et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. , 2008, Human gene therapy.
[41] Kathleen A. Marshall,et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.
[42] D. Zallen. US gene therapy in crisis. , 2000 .
[43] Z. Eshhar,et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[44] A. J. Roman,et al. Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. , 2013, Human molecular genetics.
[45] A. Terzic,et al. Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[46] D. Maloney,et al. CD 20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD 28 and 4-1 BB domains : pilot clinical trial results , 2012 .
[47] A. Lawson,et al. Artificial T-cell receptors. , 2003, Cytotherapy.
[48] D Teichler Zallen,et al. US gene therapy in crisis. , 2000, Trends in genetics : TIG.